Literature DB >> 14174052

PENICILLAMINE THERAPY FOR HEPATOLENTICULAR DEGENERATION.

I STERNLIEB, I H SCHEINBERG.   

Abstract

Entities:  

Keywords:  AMENORRHEA; AVITAMINOSIS; BONE AND BONES; COPPER; DERMATITIS MEDICAMENTOSA; DESENSITIZATION; DIET; DRUG THERAPY; EYE MANIFESTATIONS; HEPATOLENTICULAR DEGENERATION; HYPERSPLENISM; KIDNEY; LEUKOPENIA; LIVER; METABOLISM; NEUROLOGIC MANIFESTATIONS; PENICILLAMINE; TOXICOLOGIC REPORT

Mesh：

Substances：

Year:  1964        PMID： 14174052     DOI： 10.1001/jama.1964.03070100042008

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  20 in total

1.  Serum immunoglobulins in D-penicillamine-treated cystinurics.

Authors:  A D Stephens; J C Fenton
Journal:  Proc R Soc Med       Date:  1977

2.  Wilson's disease with severe hepatic insufficiency: beneficial effects of early administration of D-penicillamine.

Authors:  F Durand; J Bernuau; E Giostra; G Mentha; D Shouval; C Degott; J P Benhamou; D Valla
Journal:  Gut       Date:  2001-06       Impact factor: 23.059

3.  AGRANULOCYTOSIS AFTER PENICILLAMINE AND ANTAZOLINE.

Authors:  S SELANDER; K CRAMER
Journal:  Br Med J       Date:  1965-07-17

4.  New Agent in the Treatment of Cystinuria: N-acetyl-D-penicillamine.

Authors:  G S Stokes; J T Potts; M Lotz; F C Bartter
Journal:  Br Med J       Date:  1968-02-03

5.  Orthotopic liver transplantation for Wilson's disease.

Authors:  R S DuBois; D O Rodgerson; G Martineau; G Shroter; G Giles; J Lilly; C G Halgrimson; T E Starzl; I Sternlieb; I H Scheinberg
Journal:  Lancet       Date:  1971-03-13       Impact factor: 79.321

6.  Use of the 198Au liver scan in assessing the therapeutic effect of penicillamine in Wilson's disease.

Authors:  T Chajek
Journal:  Postgrad Med J       Date:  1974-01       Impact factor: 2.401

Review 7.  Drug-induced taste and smell disorders. Incidence, mechanisms and management related primarily to treatment of sensory receptor dysfunction.

Authors:  R I Henkin
Journal:  Drug Saf       Date:  1994-11       Impact factor: 5.606

8.  Ceruloplasmin in Wilson's disease.

Authors:  N A Holtzman; M A Naughton; F L Iber; B M Gaumnitz
Journal:  J Clin Invest       Date:  1967-06       Impact factor: 14.808

9.  Changes in the distribution of hepatic copper in relation to the progression of Wilson's disease (hepatolenticular degeneration).

Authors:  S Goldfischer; I Sternlieb
Journal:  Am J Pathol       Date:  1968-12       Impact factor: 4.307

10.  A screening test for Wilson's disease and its application to psychiatric patients.

Authors:  D W Cox
Journal:  Can Med Assoc J       Date:  1967-01-14       Impact factor: 8.262
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.